Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis

Published:2012-01-10 Issue:2 Volume:11 Page:91-96
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceut. Statist.

Author:

Mander Adrian P.¹,Wason James M.S.¹,Sweeting Michael J.¹,Thompson Simon G.¹

Affiliation:

1. MRC Biostatistics Unit Hub in Trials Methodology Research, Institute of Public Health; University Forvie Site; Cambridge CB2 0SR; UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Reference20 articles.

1. New guidelines to evaluate the response to treatment in solid tumours;Therasse;Journal of the National Cancer Institute,2000

2. Optimal two-stage designs for phase II clinical trials;Simon;Controlled Clinical Trials,1989

3. Randomised phase II designs in cancer clinical trials: current status and future directions;Lee;Journal of Clinical Oncology,2005

4. Optimal three-stage designs for phase II cancer clinical trials;Chen;Statistics in Medicine,1997

5. Optimal and minimax three-stage designs for phase II oncology clinical trials;Chen;Contemporary Clinical Trials,2008

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial;Clinical Trials;2023-01-17

2. Optimised point estimators for multi-stage single-arm phase II oncology trials;Journal of Biopharmaceutical Statistics;2022-02-23

3. A stochastically curtailed single‐arm phase II trial design for binary outcomes;Journal of Biopharmaceutical Statistics;2022-01-25

4. Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately;JCO Precision Oncology;2021-11

5. Accounting for variation in the required sample size in the design of group-sequential trials;Contemporary Clinical Trials;2021-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3